

Edgar Filing: PHARMION CORP - Form 8-K

PHARMION CORP
Form 8-K
December 15, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) December 14, 2004

Pharmion Corporation

(Exact name of registrant as specified in its charter)

Delaware ----- (State or other jurisdiction of incorporation)	000-50447 ----- (Commission File Number)	84-1521333 ----- (IRS Employer Identification No.)
------------------------------------------------------------------------	---------------------------------------------------	-------------------------------------------------------------

2525 28th Street, Boulder, Colorado ----- (Address of principal executive offices)	80301 ----- (Zip Code)
------------------------------------------------------------------------------------------	------------------------------

Registrant's telephone number, including area code 720-564-9100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: PHARMION CORP - Form 8-K

Item 8.01 Other Events.

On December 14, 2004, Erle T. Mast, our Chief Financial Officer, Judith A. Hemberger, our Chief Operating Officer and a member of our Board of Directors, and Gillian C. Ivers-Read, our Vice President Clinical Development and Regulatory Affairs, adopted pre-arranged stock trading plans in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934 and our insider trading policy.

The plans allow for sales of up to 27,500 shares of our common stock held by Mr. Mast, 71,995 shares of our common stock held by Ms. Hemberger and 15,202 shares of our common stock held by Ms. Ivers-Read in a systematic manner during a period commencing in February 2005 and ending in December 2005 and subject to our common stock trading above certain pre-arranged minimum prices. A portion of the shares to be sold under these plans will be issued pursuant to the exercise of existing stock options held by the executives.

Sales made pursuant to these plans will be disclosed publicly through Form 4 and Form 144 filings with the Securities and Exchange Commission.

These plans will permit certain of our executive officers to sell a portion of their holdings in our common stock over time as part of their respective long-term strategies for asset diversification and tax planning.

Rule 10b5-1 allows corporate officers to establish prearranged written plans to buy or sell a specified number of shares of company stock over a set period of time. A plan must be adopted in good faith at a time when the corporate officer does not possess material nonpublic information about the company. Once a plan is established, the executive does not retain any discretion over the subsequent sales of the shares.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMION CORPORATION

Date: December 14, 2004

By: /s/ Erle T. Mast

Erle T. Mast
Chief Financial Officer

3